{"id":937240,"date":"2026-02-17T10:17:41","date_gmt":"2026-02-17T15:17:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/"},"modified":"2026-02-17T10:17:41","modified_gmt":"2026-02-17T15:17:41","slug":"briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/","title":{"rendered":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT\u2122 plus immune check point inhibitor<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Fifth consecutive positive DSMB recommendation supports the favorable safety profile observed to date<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Feb.  17, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell\u2019s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PDUNQX61kMTcEfjgZpCUkA-gNGenDVZBLAcDZA5TX-P_6gpHf9Q18Qts16JM7pnsi3GuTJTcm0YbAepo55TbuLxooo14Thha2WIfMWi5bMHjty_hahJZ6S6WlYgi7hF4zWwgmL6mT7hAPp7OhNNiLfPayhyED_aZ52crMttgPuKanJV2v-XClbTZ7VRDV0S-7CKy_7dFeYqwt6FXAFcpo8Wue9XJ39t3J-uYWFmc2alBy2uPcco_asHZWKDM9YBW3uFRoPYoUE5N2H6JG1BVXkKGAXQPVGmgBewhOO5WPIo=\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>).<\/p>\n<p align=\"justify\">Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell\u2019s ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer.<\/p>\n<p align=\"justify\">\u201cThis marks the fifth consecutive DSMB review supporting the continued conduct of BriaCell\u2019s pivotal Phase 3 Bria-ABC study,\u201d said Dr. William V. Williams, President and Chief Executive Officer of BriaCell. \u201cWe are encouraged by the DSMB\u2019s ongoing confirmation of the safety profile of the Bria-IMT regimen and remain focused on advancing this program for patients with limited treatment options. We look forward to providing additional clinical updates as the study progresses.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <u>https:\/\/briacell.com\/.<\/u><\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about Bria-IMT\u2019s safety and tolerability profile; the continued conduct and advancement of BriaCell\u2019s pivotal Phase 3 Bria\u2011ABC study under FDA Fast Track designation; and Bria-IMT\u2019s potential as a transformative immunotherapy for patients with metastatic breast cancer, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5x81YWTyj778x7TLmhOFWdf4sEmNFY2j6JGOvU0kZKqA70BaVOjCJadKt01jitQRNzpG3CSeE1SZnuAoXjhmzf_3hBeX8DH5V4E7P1zp7m0=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/u><\/strong>\u00a0and on EDGAR at <strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5x81YWTyj778x7TLmhOFWUs4Wzx2iazC86b-n5fnmJ4bFzFUpaYncc0YzSBLzwVV9RtqEfyUfmw0aF4OtGqLgw==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a><\/u><\/strong>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><u>info@briacell.com<\/u>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <u>investors@briacell.com<\/u>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWQ2OGYzYzgtYjg3Ny00MTZmLTg0YjEtYzlmMDI4N2U4MzNhLTExMDIyMjktMjAyNi0wMi0xNy1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT\u2122 plus immune check point inhibitor Fifth consecutive positive DSMB recommendation supports the favorable safety profile observed to date Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell\u2019s pivotal Phase 3 Bria-ABC study of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937240","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT\u2122 plus immune check point inhibitor Fifth consecutive positive DSMB recommendation supports the favorable safety profile observed to date Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell\u2019s pivotal Phase 3 Bria-ABC study of &hellip; Continue reading &quot;BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-17T15:17:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer\",\"datePublished\":\"2026-02-17T15:17:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/\"},\"wordCount\":648,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/\",\"name\":\"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=\",\"datePublished\":\"2026-02-17T15:17:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk","og_description":"Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell\u2019s pivotal Phase 3 study of Bria-IMT\u2122 plus immune check point inhibitor Fifth consecutive positive DSMB recommendation supports the favorable safety profile observed to date Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell\u2019s pivotal Phase 3 Bria-ABC study of &hellip; Continue reading \"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-17T15:17:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer","datePublished":"2026-02-17T15:17:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/"},"wordCount":648,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/","name":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=","datePublished":"2026-02-17T15:17:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2OCM3NDI4MTI2IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-positive-recommendation-from-data-safety-monitoring-board-dsmb-for-phase-3-study-in-metastatic-breast-cancer-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937240"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937240\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}